Nexalin Technology (NXL) Long-Term Investments (2023 - 2024)
Nexalin Technology's (NXL) quarterly Long-Term Investments came in at $864.0 in Q4 2024, down 99.1% year-on-year from $96000.0 in Q1 2024, and down 99.14% quarter-over-quarter from $100651.0 in Q3 2024.
Nexalin Technology (NXL) Long-Term Investments (2023 - 2024) Analysis & Trends
Nexalin Technology's Long-Term Investments history runs 2 years deep, the most recent figure standing at $864.0 for Q4 2024.
- On a quarterly basis, Long-Term Investments fell 99.1% year-over-year to $864.0 in Q4 2024; TTM through Dec 2024 was $864.0, a 99.1% decrease from a year earlier, with the FY2024 full-year figure at $864.0, down 99.1% from the prior year.
- Long-Term Investments slipped to $864.0 in Q4 2024 per NXL's latest filing, from $100651.0 in the prior quarter.
- Across five years, Long-Term Investments topped out at $101783.0 in Q1 2024 and bottomed at $864.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.09 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | - |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 285.60 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 166.25 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | - |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 121.00 Mn |
| 10 | Nexalin Technology | 9.32 Mn | 6.61 Mn | 13,133.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 864.00 |
| Sep 30, 2024 | 100,651.00 |
| Jun 30, 2024 | 100,492.00 |
| Mar 31, 2024 | 101,783.00 |
| Dec 31, 2023 | 96,000.00 |
| Sep 30, 2023 | 96,000.00 |